- 10:46 PM Astec LifeSciences to start a project in Q3FY11
- 09:24 PM Student visa applications to US, UK see 25% drop
- 08:18 PM November 26: Events to watch out for
- 07:40 PM ITC rules out hostile takeover of East India Hotel...
- 07:34 PM Godrej, Marico eye UK-based skincare brand Simple:...
- 06:46 PM Nirmal Bang's evening guide on commodity
- 06:43 PM Shankar Sharma case: SAT extends interim stay till...
- 06:33 PM Balrampur Chini FY09 PAT up 167% at Rs 209 cr
- 06:20 PM ToI at No1 spot in English daily, says readership ...
- 06:14 PM After market report by Nirmal Bang



Aurobindo Pharma Limited is pleased to announce that the company has received two more approvals from the US FDA for Bisoprolol 5 mg, 10 mg & Amoxicillin oral suspension 200mgml, and 400mgml. This is Aurobindo’s 34th & 35th generic approval given by US FDA respectively.
Amoxicillin oral suspension is a Beta-lactam antibiotic used often in treating respiratory infections. GSK is the inventor of this antibiotic and is marketed under the brand name Amoxil.
Bisoprolol is a beta1-selective (cardioselective) adrenoceptor-blocking agent. It belongs to the group called Beta-blockers. Bisoprolol tablets are employed in managing cardiovascular diseases such as hypertension, coronary heart diseases and arrhythmias etc. Bisoprolol is the original product of MS Duramed Pharms Barr and is known as Zebeta.
These two products currently command a market size of USD 100 mio (appx) in USA which enhances Aurobindo’s opportunity in Generics business.
Sourced From: Aurobindo Pharma Limited
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Ex-bonus, RIL will see correction: SP Tulsian

- Sudarshan Sukhani's top five picks for today's trade

- Mkts to remain strong; bet on midcaps: Ramesh Damani
- Ganeshaspeaks: Market prediction for Nov 25
- Nifty to test 5500 post 5-7% correction: JM Financial

- Expert sector picks to power your portfolio ahead

- Mah Satyam looks at out-of-court settlement with creditors

- Below Rs 94, Mahindra Satyam can test Rs 85: Bhambwani

- S&P raises fears over health of some banks
Source: ft.com
- Auto sector growth to push up demand for rubber
Source: Business Line
- High networth individuals see glitter in commodities
Source: Business Line
- Tatas may launch electric Indica by early 2011
Source: Business Line










